Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover.

PubWeight™: 5.58‹?› | Rank: Top 1%

🔗 View Article (PMC 2118466)

Published in J Exp Med on September 24, 2007

Authors

Jorge R Almeida1, David A Price, Laura Papagno, Zaïna Aït Arkoub, Delphine Sauce, Ethan Bornstein, Tedi E Asher, Assia Samri, Aurélie Schnuriger, Ioannis Theodorou, Dominique Costagliola, Christine Rouzioux, Henri Agut, Anne-Geneviève Marcelin, Daniel Douek, Brigitte Autran, Victor Appay

Author Affiliations

1: Cellular Immunology Laboratory, U543, Institut National de la Santé et de la Recherche Médicale, Avenir Group, 75013 Paris, France.

Articles citing this

(truncated to the top 100)

SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A (2011) 5.78

Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood (2009) 4.80

Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med (2009) 3.94

T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol (2010) 3.39

Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity (2010) 3.25

Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J Exp Med (2008) 3.20

Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog (2010) 2.99

Structural and functional constraints limit options for cytotoxic T-lymphocyte escape in the immunodominant HLA-B27-restricted epitope in human immunodeficiency virus type 1 capsid. J Virol (2008) 2.35

Immune-driven recombination and loss of control after HIV superinfection. J Exp Med (2008) 2.34

Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood (2009) 2.33

Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood (2008) 2.30

Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate (2009) 2.17

T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol (2009) 2.17

Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet (2013) 2.11

TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat Immunol (2012) 2.04

The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med (2010) 2.03

Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection. J Exp Med (2009) 2.03

HIV and HLA class I: an evolving relationship. Immunity (2012) 1.91

Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells. J Virol (2008) 1.90

Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J Virol (2009) 1.84

IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc Natl Acad Sci U S A (2008) 1.84

Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol (2009) 1.83

Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation. J Virol (2008) 1.82

Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy. J Virol (2008) 1.79

A high-throughput single-cell analysis of human CD8⁺ T cell functions reveals discordance for cytokine secretion and cytolysis. J Clin Invest (2011) 1.75

Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med (2011) 1.73

Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol (2010) 1.66

Protective HIV-specific CD8+ T cells evade Treg cell suppression. Nat Med (2011) 1.66

Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J Virol (2008) 1.66

Th17 cells in cancer: help or hindrance? Carcinogenesis (2011) 1.63

Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther (2009) 1.59

Association of HIV-specific and total CD8+ T memory phenotypes in subtype C HIV-1 infection with viral set point. J Immunol (2009) 1.49

Continuous Effector CD8(+) T Cell Production in a Controlled Persistent Infection Is Sustained by a Proliferative Intermediate Population. Immunity (2016) 1.49

CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS One (2012) 1.48

Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response. J Clin Invest (2009) 1.46

Enumeration of functional T-cell subsets by fluorescence-immunospot defines signatures of pathogen burden in tuberculosis. PLoS One (2010) 1.45

Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV. Immunol Rev (2011) 1.44

High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control. J Virol (2011) 1.44

Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection. PLoS Pathog (2011) 1.42

Escape from highly effective public CD8+ T-cell clonotypes by HIV. Blood (2011) 1.39

Good cell, bad cell: flow cytometry reveals T-cell subsets important in HIV disease. Cytometry A (2010) 1.39

An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study). J Infect Dis (2011) 1.37

With minimal systemic T-cell expansion, CD8+ T Cells mediate protection of rhesus macaques immunized with attenuated simian-human immunodeficiency virus SHIV89.6 from vaginal challenge with simian immunodeficiency virus. J Virol (2008) 1.36

Evidence of CD8+ T-cell-mediated selective pressure on human immunodeficiency virus type 1 nef in HLA-B*57+ elite suppressors. J Virol (2008) 1.31

Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1. J Virol (2012) 1.29

HIV controllers with HLA-DRB1*13 and HLA-DQB1*06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses. J Virol (2010) 1.29

Functional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosis. Front Immunol (2014) 1.28

Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells. J Virol (2010) 1.26

Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses? Antiviral Res (2009) 1.25

T cell-dependence of Lassa fever pathogenesis. PLoS Pathog (2010) 1.25

AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J Infect Dis (2010) 1.24

Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol Ther (2008) 1.22

Magnitude and complexity of rectal mucosa HIV-1-specific CD8+ T-cell responses during chronic infection reflect clinical status. PLoS One (2008) 1.21

Telomerase activity of HIV-1-specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors. Blood (2008) 1.20

T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection. PLoS Pathog (2014) 1.19

HIV controller CD4+ T cells respond to minimal amounts of Gag antigen due to high TCR avidity. PLoS Pathog (2010) 1.17

Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood (2009) 1.14

Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol (2015) 1.14

HLA-associated clinical progression correlates with epitope reversion rates in early human immunodeficiency virus infection. J Virol (2008) 1.13

Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One (2010) 1.13

Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses. J Virol (2009) 1.13

Evaluating cellular polyfunctionality with a novel polyfunctionality index. PLoS One (2012) 1.11

Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses. Mol Ther (2010) 1.10

Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6. J Intern Med (2009) 1.07

Human immunodeficiency virus vaccine trials. Cold Spring Harb Perspect Med (2012) 1.05

Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells. Clin Cancer Res (2014) 1.05

Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine. PLoS One (2010) 1.05

Relevance of studying T cell responses in SIV-infected rhesus macaques. Trends Microbiol (2008) 1.05

Comparison of plasmid vaccine immunization schedules using intradermal in vivo electroporation. Clin Vaccine Immunol (2011) 1.05

Human Th1 cells that express CD300a are polyfunctional and after stimulation up-regulate the T-box transcription factor eomesodermin. PLoS One (2010) 1.04

Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells. Eur J Immunol (2013) 1.04

Magnitude, breadth, and functional profile of T-cell responses during human immunodeficiency virus primary infection with B and BF viral variants. J Virol (2008) 1.03

Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressors. PLoS One (2011) 1.02

Interleukin-2 production by polyfunctional HIV-1-specific CD8 T cells is associated with enhanced viral suppression. J Acquir Immune Defic Syndr (2011) 1.02

High CD8+ T cell activation marks a less differentiated HIV-1 specific CD8+ T cell response that is not altered by suppression of viral replication. PLoS One (2009) 1.02

Superior control of HIV-1 replication by CD8+ T cells targeting conserved epitopes: implications for HIV vaccine design. PLoS One (2013) 1.02

HIV controllers: a multifactorial phenotype of spontaneous viral suppression. Clin Immunol (2011) 1.02

Effective simian immunodeficiency virus-specific CD8+ T cells lack an easily detectable, shared characteristic. J Virol (2009) 1.01

Th17 cells and regulatory T cells in elite control over HIV and SIV. Curr Opin HIV AIDS (2011) 1.01

Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. PLoS One (2012) 1.01

Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates. J Virol (2012) 1.01

Functional avidity: a measure to predict the efficacy of effector T cells? Clin Dev Immunol (2012) 1.01

Diversity in CD8(+) T cell function and epitope breadth among persons with genital herpes. J Clin Immunol (2010) 1.01

CD8+ T-cell responses to Theileria parva are preferentially directed to a single dominant antigen: Implications for parasite strain-specific immunity. Eur J Immunol (2009) 1.00

Inhibitory potential of subpopulations of CD8+ T cells in HIV-1-infected elite suppressors. J Virol (2012) 1.00

Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection. J Virol (2009) 0.99

Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses. J Clin Invest (2015) 0.99

High avidity CD8+ T cells efficiently eliminate motile HIV-infected targets and execute a locally focused program of anti-viral function. PLoS One (2014) 0.98

Clonotype and repertoire changes drive the functional improvement of HIV-specific CD8 T cell populations under conditions of limited antigenic stimulation. J Immunol (2011) 0.98

HLA B*5701-positive long-term nonprogressors/elite controllers are not distinguished from progressors by the clonal composition of HIV-specific CD8+ T cells. J Virol (2012) 0.97

First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. J Transl Med (2012) 0.96

Primary CD8+ T cells from elite suppressors effectively eliminate non-productively HIV-1 infected resting and activated CD4+ T cells. Retrovirology (2013) 0.96

High-avidity, high-IFNγ-producing CD8 T-cell responses following immune selection during HIV-1 infection. Immunol Cell Biol (2011) 0.96

Acquisition of polyfunctionality by Epstein-Barr virus-specific CD8+ T cells correlates with increased resistance to galectin-1-mediated suppression. J Virol (2009) 0.96

Differential Gag-specific polyfunctional T cell maturation patterns in HIV-1 elite controllers. J Virol (2012) 0.95

HLA-B may be more protective against HIV-1 than HLA-A because it resists negative regulatory factor (Nef) mediated down-regulation. Proc Natl Acad Sci U S A (2012) 0.95

PD-1-mediated attrition of polyfunctional memory CD8+ T cells in chronic toxoplasma infection. J Infect Dis (2012) 0.95

Age-associated increase of low-avidity cytomegalovirus-specific CD8+ T cells that re-express CD45RA. J Immunol (2013) 0.95

CD8+ T cell control of HIV--a known unknown. PLoS Pathog (2010) 0.94

Protective immunity against hepatitis C: many shades of gray. Front Immunol (2014) 0.94

Articles cited by this

Phenotypic analysis of antigen-specific T lymphocytes. Science (1996) 24.26

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature (2006) 20.00

HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood (2006) 17.38

Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med (2006) 13.15

Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med (1997) 12.26

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med (2007) 11.80

Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med (1996) 10.49

HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol (2002) 10.37

CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med (2006) 10.34

Changes in thymic function with age and during the treatment of HIV infection. Nature (1998) 10.27

HIV evolution: CTL escape mutation and reversion after transmission. Nat Med (2004) 10.21

Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med (2002) 10.03

Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature (2001) 7.90

Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol (2001) 7.37

Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood (2002) 6.73

Evolution and transmission of stable CTL escape mutations in HIV infection. Nature (2001) 6.57

Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med (2001) 6.51

Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens (1995) 6.33

Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med (2007) 5.22

HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. PLoS Med (2006) 4.19

Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci U S A (1996) 4.11

Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors. J Immunol (2000) 3.83

T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. Immunity (2004) 3.69

Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J Exp Med (2005) 3.63

Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol (2004) 3.20

An inverse relationship between T cell receptor affinity and antigen dose during CD4(+) T cell responses in vivo and in vitro. Proc Natl Acad Sci U S A (1999) 3.15

A novel approach to the analysis of specificity, clonality, and frequency of HIV-specific T cell responses reveals a potential mechanism for control of viral escape. J Immunol (2002) 3.07

Structural determinants of T-cell receptor bias in immunity. Nat Rev Immunol (2006) 3.01

Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1. J Exp Med (1994) 2.81

Continuous recruitment of naive T cells contributes to heterogeneity of antiviral CD8 T cells during persistent infection. J Exp Med (2006) 2.55

Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-B*2705. Eur J Immunol (2005) 2.33

Hierarchies in cytokine expression profiles for acute and resolving influenza virus-specific CD8+ T cell responses: correlation of cytokine profile and TCR avidity. J Immunol (2004) 2.26

High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J Immunol (2001) 2.15

Oligoclonal expansions of CD8(+) T cells in chronic HIV infection are antigen specific. J Exp Med (1998) 2.13

Selection of T cell clones expressing high-affinity public TCRs within Human cytomegalovirus-specific CD8 T cell responses. J Immunol (2005) 2.04

Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J Infect Dis (2005) 2.03

Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol (2006) 1.99

Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proc Natl Acad Sci U S A (1997) 1.99

Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS. Proc Natl Acad Sci U S A (2004) 1.97

Age-related immune dysfunction in health and in human immunodeficiency virus (HIV) disease: association of age and HIV infection with naive CD8+ cell depletion, reduced expression of CD28 on CD8+ cells, and reduced thymic volumes. J Infect Dis (2003) 1.97

Stability and diversity of T cell receptor repertoire usage during lymphocytic choriomeningitis virus infection of mice. J Exp Med (1998) 1.93

Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection. AIDS (2000) 1.92

Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis (2005) 1.64

HIV-specific CD8 T cells express low levels of IL-7Ralpha: implications for HIV-specific T cell memory. Virology (2006) 1.54

In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity. J Virol (2000) 1.45

Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue. Trends Immunol (2002) 1.36

Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals. Blood (1999) 1.36

Correlation between breadth of memory HIV-specific cytotoxic T cells, viral load and disease progression in HIV infection. AIDS (2002) 1.35

The assessment of antigen-specific CD8+ T cells through the combination of MHC class I tetramer and intracellular staining. J Immunol Methods (2002) 1.28

Polygenic and multifactorial disease gene association in man: Lessons from AIDS. Annu Rev Genet (2000) 1.24

Clonal selection, clonal senescence, and clonal succession: the evolution of the T cell response to infection with a persistent virus. J Immunol (2002) 1.18

T cells and aging (update february 1999). Front Biosci (1999) 1.15

Articles by these authors

Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01

CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med (2004) 13.55

Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods (2003) 11.81

Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med (2002) 10.03

HIV preferentially infects HIV-specific CD4+ T cells. Nature (2002) 9.28

PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med (2006) 8.18

A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47

Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog (2013) 6.14

Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis (2008) 6.03

The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (2010) 5.85

Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med (2011) 5.35

A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med (2015) 5.30

Comparison of dynamic treatment regimes via inverse probability weighting. Basic Clin Pharmacol Toxicol (2006) 5.25

Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med (2007) 5.22

HIV disease: fallout from a mucosal catastrophe? Nat Immunol (2006) 5.08

HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00

Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS (2003) 4.43

Quantum dot semiconductor nanocrystals for immunophenotyping by polychromatic flow cytometry. Nat Med (2006) 4.41

Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol (2009) 4.38

Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood (2008) 4.34

Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS (2007) 4.31

Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol (2003) 4.15

Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol (2007) 4.14

T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol (2004) 4.02

Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol (2004) 3.99

Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS (2006) 3.82

HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis (2005) 3.77

Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol (2007) 3.69

Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52

Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr (2008) 3.44

Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol (2005) 3.36

The molecular basis for public T-cell responses? Nat Rev Immunol (2008) 3.32

HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science (2010) 3.29

Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Clin Infect Dis (2009) 3.28

Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J Exp Med (2006) 3.26

CD8+ T cell efficacy in vaccination and disease. Nat Med (2008) 3.20

Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol (2004) 3.20

Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol (2007) 3.18

Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol (2005) 3.18

Characterization of CD4(+) CTLs ex vivo. J Immunol (2002) 3.10

Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer (2004) 2.98

Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology (2008) 2.95

SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection. Blood (2007) 2.95

A patient with HIV-1 superinfection. N Engl J Med (2002) 2.93

Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest (2009) 2.92

Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS (2008) 2.84

Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol (2006) 2.82

Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr (2014) 2.79

HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol (2013) 2.78

Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS (2008) 2.74

Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J Acquir Immune Defic Syndr (2007) 2.72

Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol (2010) 2.64

Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother (2008) 2.61

Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med (2008) 2.59

Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog (2009) 2.57

Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol (2009) 2.51

When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data. Int J Biostat (2010) 2.50

Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS (2009) 2.50

Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med (2013) 2.49

Influenza burden of illness: estimates from a national prospective survey of household contacts in France. Arch Intern Med (2002) 2.48

JC viremia in natalizumab-treated patients with multiple sclerosis. N Engl J Med (2013) 2.48

Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1. Clin Infect Dis (2004) 2.46

The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J Leukoc Biol (2008) 2.44

Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog (2013) 2.44

Accelerated immune senescence and HIV-1 infection. Exp Gerontol (2007) 2.41

Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood (2009) 2.33

Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci U S A (2002) 2.32

Kaposi's sarcoma in HIV-negative men having sex with men. AIDS (2008) 2.28

Herpes simplex virus lung infection in patients undergoing prolonged mechanical ventilation. Am J Respir Crit Care Med (2007) 2.27

Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One (2009) 2.23

Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS (2008) 2.21

A mechanism for TCR sharing between T cell subsets and individuals revealed by pyrosequencing. J Immunol (2011) 2.20

Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS (2008) 2.19

Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol (2009) 2.17

Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett (2008) 2.17

Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med (2010) 2.17

Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther (2004) 2.14

Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood (2003) 2.14

Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS One (2008) 2.14

Frequent occurrence of chronic hepatitis B virus infection among West African HIV type-1-infected children. Clin Infect Dis (2008) 2.12